40,000 Shares in Caris Life Sciences, Inc. $CAI Bought by Maven Securities LTD

Maven Securities LTD bought a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 40,000 shares of the company’s stock, valued at approximately $1,079,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Caris Life Sciences by 185.0% during the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after purchasing an additional 1,587,176 shares during the period. UBS Group AG increased its position in Caris Life Sciences by 825.9% during the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock valued at $58,924,000 after purchasing an additional 1,948,107 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Caris Life Sciences by 31.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,470,295 shares of the company’s stock valued at $39,669,000 after purchasing an additional 354,104 shares during the period. Clearbridge Investments LLC increased its position in Caris Life Sciences by 2.5% during the 4th quarter. Clearbridge Investments LLC now owns 1,416,207 shares of the company’s stock valued at $38,209,000 after purchasing an additional 34,977 shares during the period. Finally, Marshall Wace LLP increased its position in Caris Life Sciences by 1,108.5% during the 4th quarter. Marshall Wace LLP now owns 1,002,734 shares of the company’s stock valued at $27,054,000 after purchasing an additional 919,759 shares during the period.

Analysts Set New Price Targets

A number of research analysts have issued reports on CAI shares. BTIG Research reduced their price objective on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. New Street Research started coverage on shares of Caris Life Sciences in a research report on Friday, May 8th. They set a “market perform” rating on the stock. Wolfe Research downgraded shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Finally, Weiss Ratings raised shares of Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $27.56.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca purchased 31,050 shares of Caris Life Sciences stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $16.15 per share, with a total value of $501,457.50. Following the transaction, the director directly owned 49,671 shares of the company’s stock, valued at $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 50.00% of the stock is owned by insiders.

Caris Life Sciences Price Performance

NASDAQ CAI opened at $17.97 on Monday. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The stock has a market cap of $5.08 billion and a price-to-earnings ratio of -2.36. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. The company’s 50-day simple moving average is $17.79.

Caris Life Sciences announced that its board has approved a stock buyback plan on Monday, June 8th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to buy up to 2.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.